Brief: Ryvu Therapeutics To Continue Development Of PRMT5 Programme

Ryvu Therapeutics SA

10/09/2024 07:57

Sept 10 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * RESOLVES TO CONTINUE DEVELOPMENT OF PRMT5 PROGRAMME
    * ITS INHIBITOR RVU 305 TO ENTER NEXT STAGE OF PRE-CLINICAL
DEVELOPMENT AND TOXICOLOGY STUDIES
    * STUDY'S GOAL TO SUBMIT NEW DRUGS FOR FIRST STAGE OF
CLINICAL
TRAILS IN H2, 2025

Source text for Eikon:  ID:nEMc9XR3ta 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))